Thierry Alcindor, MD, MSc
@Thalcin
Followers
991
Following
1K
Media
56
Statuses
846
Oncologue médical/Hématologue, sarcomes et tumeurs digestives|Medical oncologist/Hematologist, sarcomas and GI |@danafarbernews and @harvardmed
Boston, MA
Joined December 2017
pubmed.ncbi.nlm.nih.gov
We present the clinical results of a phase 2 trial combining neoadjuvant docetaxel, cisplatin, 5 Flourouracil, and the PD-L1 inhibitor avelumab in locally advanced gastro-esophageal adenocarcinoma...
Fier que l’article décrivant notre essai clinique sur le cancer gastro-oesophagien ait été retenu par @RIMUHC1 comme contribution marquante de l’année 2025! More to come in 2026.
0
0
1
Fier que l’article décrivant notre essai clinique sur le cancer gastro-oesophagien ait été retenu par @RIMUHC1 comme contribution marquante de l’année 2025! More to come in 2026.
Le Rapport annuel 2025 est en ligne! Cette édition met en lumière Des découvertes qui comptent—une recherche qui fait progresser les soins, soutient l’équité et améliore la santé. @cusm_muhc 🔗 https://t.co/kuEqDCLyQu
0
0
3
Mentee Gal Strauss @DanaFarber presenting our descriptive analysis of the #angiosarcoma microenvironment. Can we better define who responds to ICI?
0
5
14
What a tragedy indeed! Such a brilliant, generous and friendly colleague! I still remember his elogious tweet after I gave my first ASCO talk. We last worked together on a book chapter. I will definitely miss him as a colleague and a friend.
Tragedy confirmed: I just learned about the untimely passing of our colleague Dr Brian van Tine yesterday from this family member’s post; The #CTOS2025 conference will be an opportunity to mourn this light in our field and to celebrate his life
0
2
18
.@DanaFarber's @DrVinayakV spoke with @cure_today about how emerging second- and third-line therapeutic strategies and investigational agents may shift the standard of care for patients with GIST. ➡️
curetoday.com
Emerging investigational agents may shift the current standard of care for patients with the rare sarcoma known as gastrointestinal stromal tumor (GIST).
0
4
13
https://t.co/Snjp1gQvqQ If you missed ESMO#25, here is a chance to attend an official @myESMO endorsed event. Pleased to co-chair this educational program in Colorado Springs with Dr Eric Liu next weekend .
totalhealthoncology.com
8.0 CE/CME Credits & MOC Points In-Person Access Only Colorado Springs, CO
0
0
3
I always mix science and art when attending a congress abroad. Tonight at the @StaatsoperBLN . Trading Kaplan-Meier curves for some musical masterpieces.
0
0
4
Great seeing everybody! Always nice to catch up.
#ESMO25 Day 3 The GI poster session was buzzing and for good reason! @CathyEngMD @FLordick28391 @Thalcin
@myESMO
#ESMOAmbassadors
0
1
4
An intriguing presentation of legubicin in metastatic STS. Improvement of PFS vs. Doxorubicin despite only slightly higher response rate. Would like to see data on subsequent surgery and potential for combinations with other agents.
1
0
2
Great presentation by @MagnusNsurgonc of QoL after surgery: a broken pot that is put back together. It holds itself but is more fragile. #ESMO2025
0
0
3
RCT on timing of pegfilgrastrim after CT shows significantly reduced bone pain with 72-hour timing as compared to 24- and 48-hour timing #ESMO25 @myESMO @OncoAlert
1
10
17
I enjoyed being asked by students of @harvardmed to talk about my journey from @UEHAITI to @DanaFarberNews by way of @USherbrooke and @cusm_muhc /@McGillMed . Global Oncology, mentorship, career aspirations made for a terrific panel discussion with my colleague.
0
0
4
#CTOS2025 Fall Webinar dedicated to the Sarcoma of the Year - Chondrosarcoma! 📆Friday, October 17th, 9.00 AM EST! Excellent opportunity to broaden or refresh your knowledge on chondrosarcoma 🦴 Registration: https://t.co/H2CqvvH9EY
2
7
14
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology
annalsofoncology.org
The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However, there is a paucity of high-quality toxicity...
0
0
0
For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @WHO INN explainer https://t.co/CWemh6ed9x
4
35
125
An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last | JCO Oncology Practice
ascopubs.org
0
1
3
A rewarding hike in the beautiful Berkshire mountains!
0
0
1
That was a great discussion led by @JDekervel . Thanks to @myESMO for the invitation!
🎧 Another @myESMO Upper GI podcast! We break down key #ASCO25 updates in #EsophagealCancer & #GastricCancer: ✔️ CheckMate 577 ✔️ Matterhorn ✔️ DESTINY-Gastric04 ✔️ SATRi-cel (CAR-T!) With @LizzySmyth1, Sylvie Lorenzen & @ThAlcin 🎙 Listen now: https://t.co/yXBTS5k5NV
#GIonc
0
1
4